Arkstone Acquired by ARCHIMED to Boost Fight Against Infectious Disease
Deal News | Aug 04, 2025 | Archimed SAS
ARCHIMED, a healthcare-focused private equity firm, has acquired a majority stake in Arkstone Medical Solutions. Arkstone is a leader in leveraging machine learning and generative artificial intelligence for infectious disease diagnostics and antimicrobial stewardship. The Florida-based firm, established in 2018, provides advanced clinical decision support systems. This acquisition places Arkstone at the intersection of ARCHIMED’s Healthcare IT and Diagnostics sectors, identified through their MedSeg tool as a priority area. The acquisition aims to scale Arkstone’s technology globally to address antimicrobial resistance. Ari Frenkel, Arkstone’s Chief Science Officer, views this as a transformative milestone that will benefit from ARCHIMED’s global reach and healthcare expertise. ARCHIMED’s investment in Arkstone is part of its MED Rise fund, further diversifying its portfolio in healthcare with past investments like SeqCenter and FIM Medical. ARCHIMED is recognized for its top-tier performance in buyout firms worldwide.
Sectors
- Healthcare IT
- Diagnostics
- Private Equity
Geography
- United States – Arkstone is based in Florida, USA, and has operations across the US and internationally.
- France – ARCHIMED is a French private equity firm undertaking the acquisition.
Industry
- Healthcare IT – Arkstone provides Health IT solutions through advanced clinical decision support systems, leveraging machine learning and AI.
- Diagnostics – Arkstone operates in the Diagnostics industry by providing innovative diagnostic tools to transform infectious disease management.
- Private Equity – ARCHIMED is a private equity firm specializing in healthcare investments, playing a key role in the acquisition.
Financials
- 10 million to 1 billion per investment – ARCHIMED's investment range through its various fund lines, including the MED Rise fund.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Arkstone Medical Solutions | Target Company | Company | A pioneer in ML and AI-driven infectious disease diagnostics. |
| ARCHIMED SAS | Acquirer (PE Firm) | Company | A private equity firm focused on the healthcare sector. |
| Ari Frenkel, MD, MPH | Chief Science Officer | Person | CSO at Arkstone, commenting on the transformational impact of the acquisition. |
| Igor Petricca | Partner | Person | A Partner at ARCHIMED commenting on the strategic investment. |